Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 19/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 15/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGIR | P43119 | 3/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11021383 | 1.00 | PTGFR (0.74) | PTGFRPTGER3MEN1THRBKMT2A | |
| SCHEMBL11101989 | 1.00 | PTGFR (0.74) | PTGFRPTGER3MEN1THRBKMT2A | |
| SCHEMBL10780690 | 1.00 | PTGFR (0.74) | PTGFRPTGER3MEN1THRBKMT2A | |
| Enprostil SCHEMBL1650019 | 0.91 | PTGFR (0.64) | PTGFRPTGER3MEN1THRBKMT2A | |
| Enprostil SCHEMBL7107661 | 0.91 | PTGFR (0.64) | PTGFRPTGER3MEN1THRBKMT2A | |
| Enprostil SCHEMBL186877 | 0.91 | PTGFR (0.64) | PTGFRPTGER3MEN1THRBKMT2A | |
| Enprostil SCHEMBL10746954 | 0.91 | PTGFR (0.64) | PTGFRPTGER3MEN1THRBKMT2A | |
| Enprostil SCHEMBL10746961 | 0.91 | PTGFR (0.64) | PTGFRPTGER3MEN1THRBKMT2A | |
| SCHEMBL4303634 | 0.85 | PTGFR (1.00) | PTGFRPTGER3MEN1THRBKMT2A | |
| SCHEMBL4303639 | 0.85 | PTGFR (1.00) | PTGFRPTGER3MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015109112-A1 | COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS | GEMMUS PHARMA INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2015109112-A1 | COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS | GEMMUS PHARMA INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGFR 340/4885PTGER3 15/4885MEN1 3952/4885 |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGFR 340/4885PTGER3 15/4885MEN1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.